Ignite Creation Date:
2024-05-06 @ 3:30 AM
Last Modification Date:
2024-10-26 @ 11:34 AM
Study NCT ID:
NCT02304393
Status:
COMPLETED
Last Update Posted:
2019-12-13
First Post:
2014-11-26
Brief Title:
A Study of Selicrelumab RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced andor Metastatic Solid Tumors
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
An Open-Label Multicenter Dose-Escalation Phase IB Study to Investigate the Safety Pharmacokinetics Pharmacodynamics and Therapeutic Activity of Selicrelumab CD40 Agonist in Combination With Atezolizumab Anti PD-L1 in Patients With Locally Advanced andor Metastatic Solid Tumors
Status:
COMPLETED
Status Verified Date:
2019-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label multicenter study designed to assess the safety pharmacokinetics pharmacodynamics and activity of Selicrelumab administered in combination with Atezolizumab ATZ in participants with metastatic or locally advanced solid tumors The study will be conducted in two Parts I and II with Part I divided into Parts IA and IB All participants will be followed up for survival until death or loss of follow-up after the last visit or withdrawal of consent
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2014-002835-32 | EUDRACT_NUMBER | None | None |